Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Targeted Therapies in Asthma: KOL Insight 2020

Product Code:
596201506
Publication Date:
January 2020
Format:
PDF + PPTX
Licence Type:
Multi-User Licence

Targeted Therapies in Asthma: KOL Insight

Expectations that AstraZeneca's Fasenra would be a more potent anti-IL5 antagonist than GSK's Nucala or Teva's Cinqair have not been realised – why? What threat does Sanofi/Regeneron's Dupixent present to Xolair's domination in paediatric settings? Amgen/AstraZeneca's tezepelumab has the potential to change the treatment landscape but what clinical studies would KOLs like to see? North American and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Xolair is facing competition from new product launches for severe asthma. Where do KOLs see an upside?
  • What outcomes are KOLs expecting to see for Amgen/AstraZeneca's tezepelumab from the PIII NAVIGATOR and SOURCE studies?
  • KOLs welcome the paediatric approval for GSK's Nucala but why do they think uptake will be limited?
  • What do KOLs think of the potential of early stage drugs targeting the cytokine IL-33?
  • Why are KOLs enthusiastic about Sterna Biologics' first-in-class inhaled gene therapy for moderate-to-severe allergic asthma?

Examples of Therapies Covered

Xolair (omalizumab) Nucala (mepolizumab)
Fasenra (benralizumab) Dupixent (dupilumab)
Tezepelumab REGN3500/SAR440340
Etokimab (ANB020) TD-8236
GB001 PRS-060 (AZD1402)
Cinqair [US]/Cinqaero [EU] (reslizumab) SB010

Partial List of Participating KOLs

  • Professor of Pediatrics and Medicine, and Clinical Director of the Division of Allergy
    Washington University School of Medicine, USA
  • Professor of Medicine, Division of Immunology, Allergy and Rheumatology
    University of Cincinnati, USA
  • Professor of Medicine and Director of Pulmonary Function Laboratories
    David Geffen School of Medicine at UCLA, USA
  • Professor of Medicine and Head of Respiratory Medicine/ Honorary Consultant Physician
    National Heart and Lung Institute/ Royal Brompton Hospital, UK
  • Head of Pulmonology, Consultant and Professor of Respiratory Medicine
    Arnaud de Villeneuve Hospital, France
  • Professor of Medicine and Pneumology and Head of Pulmonary Medicine
    Leading university specialising in asthma and respiratory medicine, Germany
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved